Ocugen Advances Gene Therapies for Inherited Retinal Diseases, Eyes Key Milestones in 2027
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of progress in gene therapy development offers significant hope. Ocugen, Inc. recently provided a business update alongside its second-quarter 2026 financial results, highlighting advancements in its gene therapy pipeline for conditions like retinitis pigmentosa (RP) and Stargardt disease. These updates are crucial for the IRD community, as they signal potential new treatment options on the horizon.
Ocugen reported several key developments in its pursuit of treatments for blinding retinal diseases. The company completed enrollment in its Phase 3 liMeliGhT clinical trial for OCU400, a gene-agnostic therapy for retinitis pigmentosa. This trial is significant as it is described as the first and largest gene therapy registrational trial for broad RP, including patients with various genetic mutations and across different stages of the disease. Topline data from this Phase 3 trial for OCU400 is anticipated in the first quarter of 2027. Ocugen also completed dosing for OCU410ST, its gene therapy candidate for Stargardt disease, with topline results expected in the second quarter of 2027. Stargardt disease currently has no approved therapies globally.
These developments mean that the IRD community could see significant progress toward new therapeutic options in the near future. OCU400, a modifier gene therapy, aims to address a broad range of RP patients, including those with mutations in over 100 genes, unlike current therapies that target single genes. This gene-agnostic approach could potentially offer a treatment for many individuals who currently lack options. The anticipated data readouts in 2027 for both RP and Stargardt disease represent critical steps towards potential regulatory submissions and, ultimately, access for patients.
Ocugen's Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, stated that the company is focused on vision loss diseases with significant unmet medical needs and has multiple catalysts through 2028 across three distinct retinal disease indications. The company aims to file three Biologics License Applications (BLAs) by 2028. Ocugen's cash and restricted cash totaled $100.4 million as of June 30, 2026, which is expected to extend its cash runway into 2028. This financial position supports the continued advancement of its late-stage clinical programs.